Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

2014345 citationsJournal Article

Authors

In this study, brivanib as adjuvant therapy to TACE did not improve OS.

Good health and well-being

Published in: Hepatology

Volume 60, Issue 5, pp. 1697-1707

Field-Weighted Citation Impact: 11.72